BioMarin Pharmaceutical-BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales

BioMarin Pharmaceutical Inc. (BMRN) reported first-quarter 2024 adjusted earnings per share of 71 cents, beating the Zacks Consensus Estimate of 60 cents. The reported earnings rose 18.3% year over year, as higher sales were partially offset by rising R&D expenses.Total revenues were $648.8 million in the reported quarter, up 9% year over year on a reported basis and 13% on a constant currency basis. Strong sales of Voxzogo drove revenues. The top line, however, missed the Zacks Consensus Estimate of$ 649.8 ...